潜在类别分析揭示COVID-19相关ARDS亚组对糖皮质激素反应存在差异
两个亚组与既往ARDS亚表型有相当重叠。糖皮质激素治疗效应存在异质性(P=0.0295),高炎症表型死亡率改善,低炎症表型死亡率恶化,但激素治疗非随机分配。SARS-CoV-2 RT-PCR循环阈值仅在低炎症表型中与死亡率相关。
要点
- Class 2特征:促炎标志物、肌钙蛋白、肌酐、乳酸更高,碳酸氢盐和血压更低。
- 糖皮质激素治疗效应异质性检验P=0.0295,高炎症表型死亡率改善,低炎症表型死亡率恶化。
- 激素治疗非随机分配,上述治疗效应差异需前瞻性验证,不能直接作为床旁用药依据。
- SARS-CoV-2 RT-PCR循环阈值与死亡率的相关性仅在低炎症表型中观察到。
适用人群与场景
- 哥伦比亚大学欧文医学中心成人COVID-19相关ARDS患者,2020年3月2日至4月30日期间符合研究标准者共483例。
诊断标准与关键阈值
- 采用潜在类别分析,以基线临床、呼吸和实验室数据作为分区变量,两类别模型拟合最佳(P=0.0075)。
- 使用既往开发的机器学习模型将患者分类为低炎症和高炎症亚表型。
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:单中心潜在类别分析,样本量483例,人群为COVID-19相关ARDS成人。
- 主要结果:两类别模型最佳(P=0.0075),Class 2占23%,Class 1占77%。
- Class 2 vs Class 1:促炎标志物、肌钙蛋白、肌酐、乳酸更高,碳酸氢盐和血压更低。
- 两个亚组与既往ARDS亚表型有相当重叠。
- 糖皮质激素治疗效应异质性P=0.0295:高炎症表型死亡率改善,低炎症表型死亡率恶化,但激素治疗非随机分配。
- SARS-CoV-2 RT-PCR循环阈值与死亡率的相关性仅在低炎症表型中显著,高炎症表型中不显著。
证据类型、等级与局限
- 证据类型:单中心潜在类别分析(观察性研究),非随机干预分配。
- 局限:单中心、激素治疗非随机分配,治疗效应差异需前瞻性验证;原文未提及证据等级或推荐强度。
对床旁实践的改变
- 原文提示COVID-19相关ARDS可按炎症表型分层,高炎症表型使用糖皮质激素可能改善死亡率,低炎症表型可能恶化死亡率,但因激素非随机分配,不能据此直接改变床旁用药决策。
- SARS-CoV-2 RT-PCR循环阈值对死亡率的预测价值因亚表型而异,仅在低炎症表型中相关,高炎症表型中不相关。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Rationale: Two distinct subphenotypes have been identified in acute respiratory distress syndrome (ARDS), but the presence of subgroups in ARDS associated with coronavirus disease (COVID-19) is unknown. Objectives: To identify clinically relevant, novel subgroups in COVID-19-related ARDS and compare them with previously described ARDS subphenotypes. Methods: Eligible participants were adults with COVID-19 and ARDS at Columbia University Irving Medical Center. Latent class analysis was used to identify subgroups with baseline clinical, respiratory, and laboratory data serving as partitioning variables. A previously developed machine learning model was used to classify patients as the hypoinflammatory and hyperinflammatory subphenotypes. Baseline characteristics and clinical outcomes were compared between subgroups. Heterogeneity of treatment effect for corticosteroid use in subgroups was tested. Measurements and Main Results: From March 2, 2020, to April 30, 2020, 483 patients with COVID-19-related ARDS met study criteria. A two-class latent class analysis model best fit the population (P = 0.0075). Class 2 (23%) had higher proinflammatory markers, troponin, creatinine, and lactate, lower bicarbonate, and lower blood pressure than class 1 (77%). Ninety-day mortality was higher in class 2 versus class 1 (75% vs. 48%; P < 0.0001). Considerable overlap was observed between these subgroups and ARDS subphenotypes. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RT-PCR cycle threshold was associated with mortality in the hypoinflammatory but not the hyperinflammatory phenotype. Heterogeneity of treatment effect to corticosteroids was observed (P = 0.0295), with improved mortality in the hyperinflammatory phenotype and worse mortality in the hypoinflammatory phenotype, with the caveat that corticosteroid treatment was not randomized. Conclusions: We identified two COVID-19-related ARDS subgroups with differential outcomes, similar to previously described ARDS subphenotypes. SARS-CoV-2 PCR cycle threshold had differential value for predicting mortality in the subphenotypes. The subphenotypes had differential treatment responses to corticosteroids.
参考来源
- Sinha P, Furfaro D, Cummings MJ, et al. Latent Class Analysis Reveals COVID-19-related Acute Respiratory Distress Syndrome Subgroups with Differential Responses to Corticosteroids. Am J Respir Crit Care Med. 2021. PMID: 34543591. doi:10.1164/rccm.202105-1302OC
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。